U.S. markets close in 25 minutes
  • S&P 500

    4,117.63
    -46.37 (-1.11%)
     
  • Dow 30

    33,940.98
    -215.71 (-0.63%)
     
  • Nasdaq

    11,909.80
    -203.99 (-1.68%)
     
  • Russell 2000

    1,941.12
    -31.49 (-1.60%)
     
  • Crude Oil

    78.45
    +1.31 (+1.70%)
     
  • Gold

    1,887.40
    +2.60 (+0.14%)
     
  • Silver

    22.31
    +0.13 (+0.60%)
     
  • EUR/USD

    1.0714
    -0.0017 (-0.16%)
     
  • 10-Yr Bond

    3.6530
    -0.0210 (-0.57%)
     
  • GBP/USD

    1.2061
    +0.0009 (+0.08%)
     
  • USD/JPY

    131.4320
    +0.3600 (+0.27%)
     
  • BTC-USD

    22,883.50
    -292.07 (-1.26%)
     
  • CMC Crypto 200

    526.88
    -10.01 (-1.86%)
     
  • FTSE 100

    7,885.17
    +20.46 (+0.26%)
     
  • Nikkei 225

    27,606.46
    -79.01 (-0.29%)
     

Buy-rated Boston Scientific's $615 million takeover of Apollo Endosurgery is a positive, says Needham

Buy-rated Boston Scientific's $615 million takeover of Apollo Endosurgery is a positive, says Needham

Boston Scientific Corp.'s $615 million acquisition of Apollo Endosurgery Inc. announced earlier is complementary to the former's endoscopy franchise, as it leverages its gastroenterologist call point while offering the potential for it to expand into surgical endoscopy and bariatric surgery, Needham analysts aid Tuesday. The deal is expected to have no material impact on Boston Scientific's 2023 per-share earnings but to boost it after that. Needham analysts led by Mike Matson said they would wa